Quince Therapeutics (NASDAQ:QNCX) Stock Rating Upgraded by Zacks Research

Quince Therapeutics (NASDAQ:QNCX) was upgraded by investment analysts at Zacks Research to a “hold” rating in a report released on Thursday, Zacks reports.

Other research analysts also recently issued reports about the stock. Citizens Jmp raised shares of Quince Therapeutics from a “market perform” rating to an “outperform” rating and set a $77.00 target price for the company in a research report on Tuesday, September 22nd. Lifesci Capital raised Quince Therapeutics to a “strong-buy” rating in a report on Monday, June 29th. Rodman & Renshaw initiated coverage on Quince Therapeutics in a research report on Thursday, September 24th. They issued a “buy” rating and a $70.00 target price for the company. Leerink Partners started coverage on Quince Therapeutics in a research report on Wednesday, June 24th. They issued an “outperform” rating and a $80.00 target price for the company. Finally, Craig Hallum upgraded Quince Therapeutics to a “strong-buy” rating in a research note on Thursday, August 27th. Two investment analysts have rated the stock with a Strong Buy rating, six have issued a Buy rating, three have given a Hold rating and two have assigned a Sell rating to the stock. According to MarketBeat.com, Quince Therapeutics has an average rating of “Moderate Buy” and an average price target of $206.71.

Quince Therapeutics Stock Performance

Shares of NASDAQ:QNCX opened at $29.20 on Thursday. The company has a market capitalization of $29.78 million, a P/E ratio of -0.19 and a beta of 1.33. The company’s 50-day moving average is $29.83 and its 200 day moving average is $24.33. Quince Therapeutics has a fifty-two week low of $15.10 and a fifty-two week high of $909.98.

Quince Therapeutics (NASDAQ:QNCX) last posted its quarterly earnings data on Friday, August 14th. The company reported ($12.31) earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of ($28.02) by $15.71. As a group, research analysts predict that Quince Therapeutics will post -8 earnings per share for the current year.

Institutional Inflows and Outflows

Several institutional investors and hedge funds have recently bought and sold shares of the business. 683 Capital Management LLC purchased a new position in Quince Therapeutics in the 4th quarter valued at approximately $798,000. Intellectus Partners LLC purchased a new stake in shares of Quince Therapeutics during the fourth quarter worth $179,000. Finally, BlackRock Inc. purchased a new stake in shares of Quince Therapeutics during the second quarter worth $31,000. 30.75% of the stock is owned by institutional investors.

About Quince Therapeutics

Quince Therapeutics, Inc is a clinical-stage biotechnology company focused on developing treatments for rare diseases. The company’s research centers on its erythrocyte-derived extracellular vesicle (EEV) platform, which uses patients’ red blood cells to encapsulate and deliver therapeutic compounds.

Quince’s lead investigational product is eDSP, formerly known as EryDex, an autologous red-blood-cell-based formulation of dexamethasone sodium phosphate being developed for ataxia-telangiectasia (A-T).